ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Oak Hill Licenses Roche’s Rugonersen,
ScripThe proposed all-stock merger of troubled Acelyrin with Alumis, first announced on 6 February, will go forward, Acelyrin said 4 March, stating it will decline an unsolicited acquisition offer from Tan
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Regeneron Bolsters Ophthalmic Portfoli